IN2014DN05912A - - Google Patents
Info
- Publication number
- IN2014DN05912A IN2014DN05912A IN5912DEN2014A IN2014DN05912A IN 2014DN05912 A IN2014DN05912 A IN 2014DN05912A IN 5912DEN2014 A IN5912DEN2014 A IN 5912DEN2014A IN 2014DN05912 A IN2014DN05912 A IN 2014DN05912A
- Authority
- IN
- India
- Prior art keywords
- aminoamidine polymers
- aminoamidine
- polymers
- preparing
- polynucleotides
- Prior art date
Links
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 abstract 7
- 229920000642 polymer Polymers 0.000 abstract 7
- 238000012377 drug delivery Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 239000007858 starting material Substances 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 1
- 150000001299 aldehydes Chemical class 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 150000002527 isonitriles Chemical class 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000000693 micelle Substances 0.000 abstract 1
- 239000011859 microparticle Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000004033 plastic Substances 0.000 abstract 1
- 229920003023 plastic Polymers 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G12/00—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen
- C08G12/02—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes
- C08G12/04—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes with acyclic or carbocyclic compounds
- C08G12/06—Amines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G12/00—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen
- C08G12/02—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes
- C08G12/26—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes with heterocyclic compounds
- C08G12/34—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes with heterocyclic compounds and acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polyamides (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576899P | 2011-12-16 | 2011-12-16 | |
| PCT/US2012/069961 WO2013090861A1 (en) | 2011-12-16 | 2012-12-15 | Alpha-aminoamidine polymers and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN05912A true IN2014DN05912A (enExample) | 2015-06-05 |
Family
ID=47501483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN5912DEN2014 IN2014DN05912A (enExample) | 2011-12-16 | 2012-12-15 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9872911B2 (enExample) |
| EP (1) | EP2791210A1 (enExample) |
| CN (1) | CN104245794A (enExample) |
| AU (1) | AU2012351967A1 (enExample) |
| BR (1) | BR112014014599A8 (enExample) |
| CA (1) | CA2859205A1 (enExample) |
| EA (1) | EA201491185A1 (enExample) |
| IN (1) | IN2014DN05912A (enExample) |
| WO (1) | WO2013090861A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1583562T1 (sl) | 2003-01-06 | 2011-10-28 | Angiochem Inc | AngioPep-1, sorodne spojine in njihove uporabe |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| CA2740316A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
| CA2740317A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Etoposide and doxorubicin conjugates for drug delivery |
| CA2745524C (en) | 2008-12-05 | 2020-06-09 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| CN102300987A (zh) | 2008-12-17 | 2011-12-28 | 安吉奥开米公司 | 膜型-1基质金属蛋白抑制剂及其用途 |
| ES2729261T3 (es) | 2009-04-20 | 2019-10-31 | Angiochem Inc | Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2 |
| RU2012103240A (ru) | 2009-07-02 | 2013-08-10 | Ангиокем Инк. | Мультимерные пептидные конъюгаты и их применение |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| ES3005233T3 (en) | 2010-10-01 | 2025-03-14 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| AU2012352180A1 (en) | 2011-12-16 | 2014-07-31 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3041934A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| CA2951707A1 (en) | 2014-06-10 | 2015-12-17 | Massachusetts Institute Of Technology | Method for gene editing |
| US20170204152A1 (en) | 2014-07-16 | 2017-07-20 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| US20170210788A1 (en) | 2014-07-23 | 2017-07-27 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
| CA2989400A1 (en) | 2015-06-15 | 2016-12-22 | Angiochem Inc. | Ang1005 for the treatment of leptomeningeal carcinomatosis |
| KR20210102870A (ko) | 2018-08-30 | 2021-08-20 | 테나야 테라퓨틱스, 인코포레이티드 | 미오카르딘 및 ascl1을 사용한 심장 세포 재프로그래밍 |
| AU2019345067A1 (en) * | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| US20230137971A1 (en) | 2019-07-11 | 2023-05-04 | Tenaya Therapeutics Inc. | Cardiac cell reprogramming with micrornas and other factors |
| US11773391B2 (en) | 2020-04-01 | 2023-10-03 | University of Pittsburgh—of the Commonwealth System of Higher Education | Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19 |
| CN112876677B (zh) * | 2020-12-29 | 2022-05-06 | 浙江大学杭州国际科创中心 | 一种多巴胺功能化聚(β-氨基酯)及其制备方法和应用 |
| CN114315889B (zh) * | 2021-12-20 | 2024-03-22 | 广东万木新材料科技有限公司 | 一种双官能有机二硅醚类化合物及其合成方法 |
| CN117003792B (zh) * | 2023-07-11 | 2025-11-07 | 西北工业大学 | 一种磷化对羟基苯甲醛类化合物及其辅助制备奥曲肽的方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5155174A (en) | 1989-05-08 | 1992-10-13 | American Cyanamid Company | Surface-modified polyacrylonitrile fibrous substrates |
| US5922304A (en) | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
| US6537246B1 (en) | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
| US7091192B1 (en) | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
| US7375096B1 (en) | 1998-12-04 | 2008-05-20 | California Institute Of Technology | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network |
| SE519326C2 (sv) * | 1999-11-22 | 2003-02-11 | Astrazeneca Ab | Funktionaliserade polymera reagens innefattande en syralabil isonitrildel samt förfarande för dess framställning |
| US7427394B2 (en) | 2000-10-10 | 2008-09-23 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
| EP2428568B1 (en) | 2001-09-28 | 2018-04-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
| US20030211139A1 (en) * | 2002-05-07 | 2003-11-13 | Thierry Legon | Dispersions of lipid particles for use as therapeutic and cosmetic agents and intracellular delivery vehicles |
| TW200640493A (en) | 2005-02-16 | 2006-12-01 | Insert Therapeutics Inc | Cyclodextrin-based polymers for therapeutics delivery |
| EP2476756A1 (en) | 2005-06-15 | 2012-07-18 | Massachusetts Institute of Technology | Amine-containing lipids and uses thereof |
| EP2032652A4 (en) | 2006-06-05 | 2011-08-17 | Massachusetts Inst Technology | NETWORKED DEVELOPABLE POLYMERS AND ITS USE |
| CA2658768C (en) | 2006-07-21 | 2016-05-17 | Massachusetts Institute Of Technology | End-modified poly(beta-amino esters) and uses thereof |
| US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| US20090191244A1 (en) | 2007-09-27 | 2009-07-30 | Children's Medical Center Corporation | Microbubbles and methods for oxygen delivery |
| CN104910025B (zh) | 2008-11-07 | 2019-07-16 | 麻省理工学院 | 氨基醇类脂质和其用途 |
-
2012
- 2012-12-15 CN CN201280069821.XA patent/CN104245794A/zh active Pending
- 2012-12-15 AU AU2012351967A patent/AU2012351967A1/en not_active Abandoned
- 2012-12-15 US US14/364,028 patent/US9872911B2/en active Active
- 2012-12-15 WO PCT/US2012/069961 patent/WO2013090861A1/en not_active Ceased
- 2012-12-15 EP EP12809954.6A patent/EP2791210A1/en not_active Withdrawn
- 2012-12-15 CA CA2859205A patent/CA2859205A1/en not_active Abandoned
- 2012-12-15 BR BR112014014599A patent/BR112014014599A8/pt not_active IP Right Cessation
- 2012-12-15 EA EA201491185A patent/EA201491185A1/ru unknown
- 2012-12-15 IN IN5912DEN2014 patent/IN2014DN05912A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104245794A (zh) | 2014-12-24 |
| BR112014014599A2 (pt) | 2017-06-13 |
| US20140322309A1 (en) | 2014-10-30 |
| BR112014014599A8 (pt) | 2017-06-13 |
| WO2013090861A1 (en) | 2013-06-20 |
| AU2012351967A1 (en) | 2014-07-17 |
| CA2859205A1 (en) | 2013-06-20 |
| US9872911B2 (en) | 2018-01-23 |
| EP2791210A1 (en) | 2014-10-22 |
| EA201491185A1 (ru) | 2015-05-29 |
| WO2013090861A8 (en) | 2013-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN05912A (enExample) | ||
| MX353900B (es) | Lipidoides de aminoalcohol y usos de los mismos. | |
| JP2016222689A5 (ja) | 合成ペプチド及び乾燥粉末薬剤輸送システム | |
| IN2014DN00101A (enExample) | ||
| EP4331667A3 (en) | Compositions comprising a delivery agent and preparation thereof | |
| WO2017044894A3 (en) | Cartilage-homing peptides | |
| MX2010006799A (es) | Benzofuropirimidinonas como inhibidores de la proteina cinasa. | |
| EP2536736A4 (en) | PREPARATION OF 6'-O-SIALYLLACTOSE AND INTERMEDIATE PRODUCTS THEREOF | |
| JP2017533218A5 (enExample) | ||
| EP4286400A3 (en) | Improved peptide pharmaceuticals | |
| MD20140072A2 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| MX353036B (es) | Articulos solubles de dosis unitaria que comprenden un polimero cationico. | |
| PE20170312A1 (es) | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso | |
| IN2013DN02524A (enExample) | ||
| EP2595633A4 (en) | METHOD FOR INTRAVENOUS ADMINISTRATION OF GLYBURID AND OTHER MEDICAMENTS | |
| EP3747891A3 (en) | Compositions and methods for conjugating oligonucleotides | |
| PH12013500223A1 (en) | Oral care product and methods of use and manufacture thereof | |
| UA117490C2 (uk) | Сполуки ізоіндоліну або ізохіноліну, спосіб їх одержання і фармацевтичні композиції, що їх містять | |
| ATE530188T1 (de) | Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs | |
| IN2014MN02248A (enExample) | ||
| SA517381298B1 (ar) | تركيبة صيدلية بثبات محسن | |
| GB201002413D0 (en) | Nucleic acid complexes | |
| MX2018012682A (es) | Conjugados de acido hialuronico y usos de los mismos. | |
| EP4477222A3 (en) | Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt | |
| MX341642B (es) | Composicion de liberacion sostenida que contiene peptidos como ingredientes activos. |